NCT00075829 · OUTCOME

Incidences of Chronic GVHD

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) · Source last updated 2021-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Incidence and severity of chronic GVHD will be scored according to the BMT clinical trials network Manual of Procedures.

Analysis population: GVHD was only assessed on the Auto-Allo arm for standard risk patients that completed second transplant

Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Auto-Allo Standard Risk	156

1 year

Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Auto-Allo Standard Risk	47	Not reported	39	56	Not reported

2 years

Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Auto-Allo Standard Risk	54	Not reported	46	63	Not reported

Complete source fields

classes

denoms

description

Incidence and severity of chronic GVHD will be scored according to the BMT clinical trials network Manual of Procedures.

dispersion Type

95% Confidence Interval

groups

param Type

NUMBER

population Description

GVHD was only assessed on the Auto-Allo arm for standard risk patients that completed second transplant

reporting Status

POSTED

time Frame

Years 1 and 2

title

Incidences of Chronic GVHD

type

SECONDARY

unit Of Measure

percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice